NUC-7738
Based on 1 publication(s) in Google Scholar
NUC-7738, an aryloxy phosphoramidate of 3′-Deoxyadenosine, is a 5′-aryloxy phosphoramidate prodrug of 3′-Deoxyadenosine (3′-dA). NUC-7738 has potent cytotoxic activity against a panel of hematological cancer cell lines. NUC-7738 can be used in research of cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 97.01%
- CAS No.: 2348493-39-8
- 화학식: C26H29N6O7P
- 분자량:568.52
-
보관:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) NUC-7738
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 5637 | IC50 |
47.45 μM
Compound: NUC7738
|
Cytotoxicity against human 5637 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human 5637 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| A498 | IC50 |
58.05 μM
Compound: NUC7738
|
Cytotoxicity against human A498 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human A498 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| CAKI-2 | IC50 |
102.45 μM
Compound: NUC7738
|
Cytotoxicity against human CAKI-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human CAKI-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| COLO 205 | IC50 |
27.75 μM
Compound: NUC7738
|
Cytotoxicity against human COLO 205 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human COLO 205 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| HepG2 | IC50 |
25.24 μM
Compound: NUC7738
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| HL-60 | IC50 |
38.4 μM
Compound: NUC7738
|
Cytotoxicity against human HL-60 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human HL-60 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| HT-29 | IC50 |
9.47 μM
Compound: NUC7738
|
Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| K562 | IC50 |
10.34 μM
Compound: NUC7738
|
Cytotoxicity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| KG-1 | IC50 |
23.51 μM
Compound: NUC7738
|
Cytotoxicity against human KG-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human KG-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| MCF7 | IC50 |
3.69 μM
Compound: NUC7738
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| MDA-MB-231 | IC50 |
19.42 μM
Compound: NUC7738
|
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| MIA PaCa-2 | IC50 |
7.41 μM
Compound: NUC7738
|
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| MOLT-4 | IC50 |
4.67 μM
Compound: NUC7738
|
Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| PC-3 | IC50 |
51.18 μM
Compound: NUC7738
|
Cytotoxicity against human PC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human PC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| RL | IC50 |
34.65 μM
Compound: NUC7738
|
Cytotoxicity against human RL cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human RL cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
NUC-7738 (compound 7a; 0-198 μM; 72 h; CCRF-CEM, HL-60, KG-1, MOLT-4, K562, MV4-11, THP-1, HEL92, NCI-H929, RPMI-8226, Jurkat, Z138, RL, HS445, HepG2, MCF-7, Bx-PC-3, HT29, MIA PaCa-2 and SW620 cells) has anticancer activity and cytotoxic activity against a lineage of leukocytes with LC50 values of <30 μM[1].
NUC-7738 (1 μM) has good stability in human hepatocytes with t1/2 value of 48.1 min[1].
NUC-7738 has increased stability in human plasma compared to the parent nucleoside, with no change in plasma concentration up to 4 h[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2348493-39-8
-
Appearance Solid
-
분자량 568.52
-
화학식 C26H29N6O7P
-
Color White to off-white
-
SMILES
NC1=NC=NC2=C1N=CN2[C@@H]3O[C@H](COP(N[C@@H](C)C(OCC4=CC=CC=C4)=O)(OC5=CC=CC=C5)=O)C[C@H]3O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Biochem Mol Toxicol
NUC7738 Induces Apoptosis Through Modulating Stability of P53 in Esophageal Cancer Cells. [Abstract]2025 Feb;39(2):e70175. PMID: 39967332
용액&용해도
DMSO : 100 mg/mL (175.90 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7590 mL | 8.7948 mL | 17.5895 mL | 43.9738 mL |
| 5 mM | 0.3518 mL | 1.7590 mL | 3.5179 mL | 8.7948 mL | |
| 10 mM | 0.1759 mL | 0.8795 mL | 1.7590 mL | 4.3974 mL | |
| 15 mM | 0.1173 mL | 0.5863 mL | 1.1726 mL | 2.9316 mL | |
| 20 mM | 0.0879 mL | 0.4397 mL | 0.8795 mL | 2.1987 mL | |
| 25 mM | 0.0704 mL | 0.3518 mL | 0.7036 mL | 1.7590 mL | |
| 30 mM | 0.0586 mL | 0.2932 mL | 0.5863 mL | 1.4658 mL | |
| 40 mM | 0.0440 mL | 0.2199 mL | 0.4397 mL | 1.0993 mL | |
| 50 mM | 0.0352 mL | 0.1759 mL | 0.3518 mL | 0.8795 mL | |
| 60 mM | 0.0293 mL | 0.1466 mL | 0.2932 mL | 0.7329 mL | |
| 80 mM | 0.0220 mL | 0.1099 mL | 0.2199 mL | 0.5497 mL | |
| 100 mM | 0.0176 mL | 0.0879 mL | 0.1759 mL | 0.4397 mL |